Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally.
Company facts
| Company | Vertex Pharmaceuticals Incorporated |
|---|---|
| Symbol | VRTX |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $130.42B (Massive market data, 2026-09-10) |
| Employees | 6,400 |
| Country | United States |
| Website | https://www.vrtx.com |
Trading — Vertex Pharmaceuticals Incorporated
| Last price | $515.44 |
|---|---|
| Change | 0.17% |
| Previous close | $514.56 |
| Day range | $511.81 – $522.10 |
| 50-day average | $510.30 |
| 200-day average | $467.58 |
| Average volume | 1,422,481 |
Price basis: 2026-09-11T21:00:34.095615+00:00
Valuation and financial health
| Earnings per share | $17.38 |
|---|---|
| Price / book | 6.44 |
| Price / cash flow | 30.38 |
| Enterprise value / EBITDA | 24.21 |
| Enterprise value / sales | 9.87 |
| Debt / equity | 0.00 |
| Current ratio | 3.19 |
| Dividend yield | 0.00% |
| Free cash flow | $3.80B |
| Cash ratio | 1.56 |
| Enterprise value | $124.28B |
Reported 2026-09-10
Earnings
| Report date | 2026-11-02 |
|---|---|
| Session | After Hours |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $4.40 |
| Year-ago EPS | $4.22 |
| Analyst estimates | 6 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for VRTX are on the IntelTrends dashboard.